CU20100144A7 - Composiciones vacunales a base de sticholisina encapsulada en liposomas - Google Patents

Composiciones vacunales a base de sticholisina encapsulada en liposomas

Info

Publication number
CU20100144A7
CU20100144A7 CU20100144A CU20100144A CU20100144A7 CU 20100144 A7 CU20100144 A7 CU 20100144A7 CU 20100144 A CU20100144 A CU 20100144A CU 20100144 A CU20100144 A CU 20100144A CU 20100144 A7 CU20100144 A7 CU 20100144A7
Authority
CU
Cuba
Prior art keywords
encapsulated
liposomes
immune response
sticholisine
present
Prior art date
Application number
CU20100144A
Other languages
English (en)
Inventor
Santos Liem Canet
Garay Aisel Valle
Martinez Mayra Tejuca
Valcarcel Carlos Manuel Alvarez
Quintana Rady Judith Laborde
Leal Yoelys Cruz
Lorenzo Maria Del Carmen Luzardo
Biosca Maria Eugenia Alonso
Molina Luis Enrique Fernandez
Pardillo Circe Mesa
Ruiz Maria Eliana Lanio
Santos Isabel Fabiola Pazos
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44533576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20100144(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU20100144A priority Critical patent/CU20100144A7/es
Priority to UAA201301383A priority patent/UA111944C2/uk
Priority to ARP110102211A priority patent/AR081661A1/es
Priority to TW100122821A priority patent/TWI457145B/zh
Priority to CA2802443A priority patent/CA2802443C/en
Priority to EA201291449A priority patent/EA025333B1/ru
Priority to BR112012033284-8A priority patent/BR112012033284B1/pt
Priority to JP2013517001A priority patent/JP5685646B2/ja
Priority to MX2012015173A priority patent/MX2012015173A/es
Priority to HK13104046.1A priority patent/HK1177138B/xx
Priority to PH1/2013/500036A priority patent/PH12013500036A1/en
Priority to CN201180033067.XA priority patent/CN102971011B/zh
Priority to SG2013000690A priority patent/SG186931A1/en
Priority to US13/808,276 priority patent/US8697093B2/en
Priority to EP11743950.5A priority patent/EP2591802B1/en
Priority to PE2013000004A priority patent/PE20130390A1/es
Priority to MYPI2013000019A priority patent/MY167896A/en
Priority to KR1020137000208A priority patent/KR101455055B1/ko
Priority to AU2011276812A priority patent/AU2011276812B2/en
Priority to PCT/CU2011/000004 priority patent/WO2012003814A1/es
Priority to ES11743950.5T priority patent/ES2576851T3/es
Publication of CU20100144A7 publication Critical patent/CU20100144A7/es
Priority to TNP2012000592A priority patent/TN2012000592A1/en
Priority to CO12229159A priority patent/CO6640312A2/es
Priority to CL2012003674A priority patent/CL2012003674A1/es
Priority to ZA2013/00059A priority patent/ZA201300059B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con el campo de Biotecnología aplicada a la salud humana. En la misma se describe un vehículo vacunal donde se encapsula toxinas provenientes de organismos eucariontes en liposomas de múltiples capas lipídicas obtenidos por el procedimiento de deshidratación-rehidratación cuya composición lipídica es dipalmitoilfosfatidilcolina: colesterol en una relación molar 1:1, destinadas a la administración subcutánea o intramuscular. Estas composiciones no requieren del empleo de otros adyuvantes. Las composiciones descritas posibilitan la modulación de la respuesta inmune CTL específica contra uno o varios antígenos co-encapsulados en liposomas que contienen la toxina. El vehículo vacunal de la presente invención presenta ventajas frente a otros descritos por el arte previo debido a la robustez y funcionalidad de la respuesta inmune que induce así como a sus propiedades inmumoduladoras.
CU20100144A 2010-07-06 2010-07-06 Composiciones vacunales a base de sticholisina encapsulada en liposomas CU20100144A7 (es)

Priority Applications (25)

Application Number Priority Date Filing Date Title
CU20100144A CU20100144A7 (es) 2010-07-06 2010-07-06 Composiciones vacunales a base de sticholisina encapsulada en liposomas
UAA201301383A UA111944C2 (uk) 2010-07-06 2011-05-07 Вакцинна композиція на основі стихолізину, інкапсульованого в ліпосоми
ARP110102211A AR081661A1 (es) 2010-07-06 2011-06-24 Composiciones vacunales a base de sticholisina encapsulada en liposomas
TW100122821A TWI457145B (zh) 2010-07-06 2011-06-29 以被包封於微脂粒內之蒂卡琳素（ｓｔｉｃｈｏｌｙｓｉｎ）為基礎的疫苗組成物
ES11743950.5T ES2576851T3 (es) 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsuladas en llposomas
SG2013000690A SG186931A1 (en) 2010-07-06 2011-07-05 Vaccine compositions based on sticholysin encapsulated in liposomes
PE2013000004A PE20130390A1 (es) 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsulada en liposomas
BR112012033284-8A BR112012033284B1 (pt) 2010-07-06 2011-07-05 veículo vacinal para induzir resposta imune celular, e, composição vacinal
JP2013517001A JP5685646B2 (ja) 2010-07-06 2011-07-05 リポソーム中にカプセル化されたスチコリシンに基づくワクチン組成物
MX2012015173A MX2012015173A (es) 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsulada en liposomas.
HK13104046.1A HK1177138B (en) 2010-07-06 2011-07-05 Vaccine compositions based on sticholysin encapsulated in liposomes
PH1/2013/500036A PH12013500036A1 (en) 2010-07-06 2011-07-05 Vaccine compositions based on sticholysin encapsulated into liposomes
CN201180033067.XA CN102971011B (zh) 2010-07-06 2011-07-05 基于包囊在脂质体中的海葵溶细胞素的疫苗组合物
CA2802443A CA2802443C (en) 2010-07-06 2011-07-05 Vaccine compositions based on sticholysin encapsulated in liposomes
US13/808,276 US8697093B2 (en) 2010-07-06 2011-07-05 Vaccine composition based on sticholysin encapsulated into liposomes
EP11743950.5A EP2591802B1 (en) 2010-07-06 2011-07-05 Vaccine compositions based on sticholysin encapsulated in liposomes
EA201291449A EA025333B1 (ru) 2010-07-06 2011-07-05 Вакцинный носитель для индукции клеточного иммунного ответа
MYPI2013000019A MY167896A (en) 2010-07-06 2011-07-05 Vaccine composition based on sticholysin encapsulated into liposomes.
KR1020137000208A KR101455055B1 (ko) 2010-07-06 2011-07-05 리포솜으로 캡슐화된 스티코리신에 따른 백신 조성물
AU2011276812A AU2011276812B2 (en) 2010-07-06 2011-07-05 Vaccine compositions based on sticholysin encapsulated in liposomes
PCT/CU2011/000004 WO2012003814A1 (es) 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsulada en liposomas
TNP2012000592A TN2012000592A1 (en) 2010-07-06 2012-12-13 Vaccine compositions based on sticholysin encapsulated in liposomes
CO12229159A CO6640312A2 (es) 2010-07-06 2012-12-18 Composiciones vacunales a base de sticholisina encapsulada en liposomas
CL2012003674A CL2012003674A1 (es) 2010-07-06 2012-12-21 Vehiculo vacunal para inducir respuesta inmune celular que comprende la encapsulación en vesículas lipídicas de proteínas obtenidas de la anémona stichodactyla helianthus junto con un antígeno; composicion vacunal que comprende el vehiculo vacunal; uso de la composicion para reforzamiento de la respuesta inmune.
ZA2013/00059A ZA201300059B (en) 2010-07-06 2013-01-03 Vaccine compositions based on sticholysin encapsulated in liposomes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20100144A CU20100144A7 (es) 2010-07-06 2010-07-06 Composiciones vacunales a base de sticholisina encapsulada en liposomas

Publications (1)

Publication Number Publication Date
CU20100144A7 true CU20100144A7 (es) 2012-06-21

Family

ID=44533576

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100144A CU20100144A7 (es) 2010-07-06 2010-07-06 Composiciones vacunales a base de sticholisina encapsulada en liposomas

Country Status (24)

Country Link
US (1) US8697093B2 (es)
EP (1) EP2591802B1 (es)
JP (1) JP5685646B2 (es)
KR (1) KR101455055B1 (es)
CN (1) CN102971011B (es)
AR (1) AR081661A1 (es)
AU (1) AU2011276812B2 (es)
BR (1) BR112012033284B1 (es)
CA (1) CA2802443C (es)
CL (1) CL2012003674A1 (es)
CO (1) CO6640312A2 (es)
CU (1) CU20100144A7 (es)
EA (1) EA025333B1 (es)
ES (1) ES2576851T3 (es)
MX (1) MX2012015173A (es)
MY (1) MY167896A (es)
PE (1) PE20130390A1 (es)
PH (1) PH12013500036A1 (es)
SG (1) SG186931A1 (es)
TN (1) TN2012000592A1 (es)
TW (1) TWI457145B (es)
UA (1) UA111944C2 (es)
WO (1) WO2012003814A1 (es)
ZA (1) ZA201300059B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014034669A1 (ja) * 2012-08-28 2014-03-06 国立大学法人北海道大学 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
WO2019010560A1 (en) * 2017-07-10 2019-01-17 Immmunovaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION USING LIPID VESICLE PARTICLES OF A DEFINED SIZE, AND USES THEREOF
CN113041346A (zh) * 2019-12-26 2021-06-29 复旦大学 一种细菌毒素疫苗及其在预防细菌感染中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086831C (en) 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1797895A1 (en) 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
WO2008068829A1 (ja) 2006-12-04 2008-06-12 Incorporated Administrative Agency National Agriculture And Food Research Organization バイオミネラル含有物の製造方法および有機養液栽培法

Also Published As

Publication number Publication date
EP2591802B1 (en) 2016-06-08
US20130149376A1 (en) 2013-06-13
WO2012003814A1 (es) 2012-01-12
EP2591802A1 (en) 2013-05-15
UA111944C2 (uk) 2016-07-11
CA2802443A1 (en) 2012-01-12
AU2011276812B2 (en) 2013-12-19
AU2011276812A1 (en) 2013-01-10
ES2576851T3 (es) 2016-07-11
US8697093B2 (en) 2014-04-15
PH12013500036A1 (en) 2013-02-18
HK1177138A1 (en) 2013-08-16
KR101455055B1 (ko) 2014-10-28
JP5685646B2 (ja) 2015-03-18
CO6640312A2 (es) 2013-03-22
CN102971011A (zh) 2013-03-13
CL2012003674A1 (es) 2013-07-12
BR112012033284B1 (pt) 2021-05-18
JP2013530190A (ja) 2013-07-25
EA025333B1 (ru) 2016-12-30
MY167896A (en) 2018-09-26
EA201291449A1 (ru) 2013-05-30
TWI457145B (zh) 2014-10-21
AR081661A1 (es) 2012-10-10
TN2012000592A1 (en) 2014-04-01
PE20130390A1 (es) 2013-04-11
ZA201300059B (en) 2013-09-25
SG186931A1 (en) 2013-02-28
BR112012033284A2 (pt) 2017-05-02
CA2802443C (en) 2015-03-17
CN102971011B (zh) 2014-12-03
TW201217000A (en) 2012-05-01
KR20130027547A (ko) 2013-03-15
MX2012015173A (es) 2013-02-11

Similar Documents

Publication Publication Date Title
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EP4056198A3 (en) Outer membrane vesicles
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
PH12013502174B1 (en) Vaccine delivery method
MX2017001279A (es) Usos y composiciones de la flagelina.
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
AR092372A1 (es) Formulaciones de liposomas, uso y metodo de tratamiento
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
CO6640312A2 (es) Composiciones vacunales a base de sticholisina encapsulada en liposomas
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
WO2012003361A3 (en) Nanoemulsion vaccines
IN2014CN03454A (es)
NZ596501A (en) Casb7439 constructs
EP2762153A3 (en) Vaccine composition for mucosal administration
SG10201810886YA (en) Antibody titer-increasing agent using lactic acid bacterium
CY1118402T1 (el) Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση
BR112015013190A2 (pt) preparação cosmética ou dermatológica à base de uma emulsão de água-em-óleo, uso de uma preparação, e uso de pelo menos 0,1 % em peso
WO2013173256A3 (en) New and improved influenza vaccines